JP2010529128A - レット症候群および他の障害の処置 - Google Patents

レット症候群および他の障害の処置 Download PDF

Info

Publication number
JP2010529128A
JP2010529128A JP2010511198A JP2010511198A JP2010529128A JP 2010529128 A JP2010529128 A JP 2010529128A JP 2010511198 A JP2010511198 A JP 2010511198A JP 2010511198 A JP2010511198 A JP 2010511198A JP 2010529128 A JP2010529128 A JP 2010529128A
Authority
JP
Japan
Prior art keywords
igf
igf1
administered
pro
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010511198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529128A5 (enExample
Inventor
サー，ムリガンカ
トロペア，ダニエラ
ジアコメッティ，エマニュエル
イェーニッシュ，ルドルフ
ウィルソン，ネイサン，アール．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2010529128A publication Critical patent/JP2010529128A/ja
Publication of JP2010529128A5 publication Critical patent/JP2010529128A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2010511198A 2007-06-08 2008-06-06 レット症候群および他の障害の処置 Pending JP2010529128A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93373807P 2007-06-08 2007-06-08
PCT/US2008/007107 WO2008153929A1 (en) 2007-06-08 2008-06-06 Igf for the treatment of rett syndrome and synaptic disorders

Publications (2)

Publication Number Publication Date
JP2010529128A true JP2010529128A (ja) 2010-08-26
JP2010529128A5 JP2010529128A5 (enExample) 2011-07-21

Family

ID=39891784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010511198A Pending JP2010529128A (ja) 2007-06-08 2008-06-06 レット症候群および他の障害の処置

Country Status (8)

Country Link
US (2) US7994127B2 (enExample)
EP (1) EP2164509A1 (enExample)
JP (1) JP2010529128A (enExample)
CN (1) CN101820896A (enExample)
AU (1) AU2008262387A1 (enExample)
BR (1) BRPI0812768A2 (enExample)
CA (1) CA2689549A1 (enExample)
WO (1) WO2008153929A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508744A (ja) * 2011-01-27 2014-04-10 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロピル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療
JP2016506380A (ja) * 2012-11-28 2016-03-03 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロリル−ｌ−グルタミン酸を使用する自閉症スペクトラム障害の処置
WO2021100614A1 (ja) * 2019-11-19 2021-05-27 国立大学法人京都大学 大豆ペプチド及び／又はコラーゲンペプチド含有神経心理学的機能改善剤

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
US8969295B2 (en) * 2006-04-14 2015-03-03 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
CN102348798A (zh) 2009-01-16 2012-02-08 麻省理工学院 孤独症谱系障碍的诊断和治疗
EP2571515B1 (en) 2010-05-17 2016-11-30 Icahn School of Medicine at Mount Sinai Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression
MX353285B (es) * 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
DK2734634T3 (da) * 2011-07-22 2019-10-21 Univ Chicago Igf-1 til anvendelse til behandling af migræne
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
ES2495266B8 (es) * 2013-02-13 2015-11-12 Consejo Superior De Investigaciones Científicas (Csic) Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
RU2017110868A (ru) 2014-09-25 2018-10-25 Колд Спринг Харбор Лаборатори Лечение синдрома ретта
JP6866379B2 (ja) 2016-01-26 2021-04-28 アナベックス ライフ サイエンシズ コーポレイション 神経発達障害療法
TWI601821B (zh) * 2016-04-15 2017-10-11 中央研究院 治療神經發展性疾病
WO2018217766A1 (en) 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Kcc2 expression enhancing compounds and uses thereof
CN108187031A (zh) * 2018-02-11 2018-06-22 中国人民解放军第四军医大学 rhIGF1在制备治疗脆性X综合征药物中的应用
JP2022524927A (ja) 2019-02-02 2022-05-11 ステモニックス インコーポレイティド 創薬のためのヒトスフェロイドの使用方法
JP2022547948A (ja) 2019-09-09 2022-11-16 ザ・ユニバーシティ・オブ・シカゴ 片頭痛の処置のための併用療法
WO2022055045A1 (ko) * 2020-09-08 2022-03-17 주식회사 선마린바이오테크 콜라게나제 저해 활성 펩타이드 유도체 및 이의 용도
US20240148835A1 (en) * 2021-01-28 2024-05-09 University Of Florida Research Foundation, Incorporated Treating disorders associated with dyrk1a dysfunction

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
AU637316B2 (en) 1988-01-28 1993-05-27 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
AU628322B2 (en) 1988-01-28 1992-09-17 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
SE8803847A0 (sv) 1988-10-27 1990-04-28 Kabigen Ab Neuromodulerande peptid
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
ES2101865T3 (es) 1991-08-01 1997-07-16 Genentech Inc Igf-1 para mejorar el estado neural.
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
US5420112A (en) 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US5446024A (en) 1993-12-17 1995-08-29 Genentech, Inc. Purification of insulin-like growth factor
CA2178711A1 (en) 1993-12-23 1995-06-29 Peter David Gluckman Composition and methods to improve neural outcome
US5565428A (en) 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US20020132252A1 (en) 1997-06-16 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
US7304029B1 (en) 1998-09-03 2007-12-04 Neuren Pharmaceuticals Ltd. Neuroprotective effect of growth hormone
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
WO2002016408A2 (en) 2000-08-24 2002-02-28 Neuronz Ltd. Gpe analogs
WO2002057241A1 (en) 2000-12-22 2002-07-25 Bayer Pharmaceuticals Corporation 8-(AMINOALKOXYMINO)-8H-DIBENZO[a,e]TRIAZOLO[4,5-c]CYCLOHEPTENES AS GROWTH HORMONE SECRETAGOGUES
WO2002056873A2 (en) 2000-12-22 2002-07-25 Bayer Pharmaceuticals Corporation 2-substituted dibenzo[a,e]1,2,3-triazolo[4,5-c][7]annulen-8-ones as growth hormone secretagogues
DE60217066T4 (de) 2001-02-09 2010-07-01 Genentech, Inc., South San Francisco Kristallisierung von igf-1
US7863304B2 (en) 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
EP1401808B1 (en) 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Gpe analogs and peptidomimetics
US7485630B2 (en) 2003-03-20 2009-02-03 Neuren Pharmaceuticals Limited Neuroprotective macrocyclic compounds and methods for their use
US20050027110A1 (en) 2003-07-24 2005-02-03 Michael Russell Drug delivery in the nervous system
DK2274978T3 (en) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
US20070224165A1 (en) 2003-10-23 2007-09-27 Neuren Pharmaceuticals Limited Neuroprotective Effects of Gly-Pro-Glu Following Intravenous Infusion
US20060104969A1 (en) * 2004-08-16 2006-05-18 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
JP2008511838A (ja) 2004-08-30 2008-04-17 テルシカ・インク インシュリン様成長因子欠乏疾患の診断及び治療のための方法及び装置
KR20060040550A (ko) 2004-11-05 2006-05-10 마루이시세이야쿠가부시키가이샤 인슐린유사 성장인자-1 분비촉진제
US8158582B2 (en) 2005-06-02 2012-04-17 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 deficiency
US8969295B2 (en) * 2006-04-14 2015-03-03 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6013009128; ＮＡＴＵＲＥ　ＮＥＵＲＯＳＣＩＥＮＣＥ ＶＯＬ．９，　ＮＯ．５, 200605, Ｐ．６６０-６６８ *
JPN6013009131; ＣＨＥＭＯＴＨＥＲＡＰＹ ＶＯＬ．５２, 2006, Ｐ．２７９-２８１ *
JPN6013009132; ＢＩＯＯＲＧＡＮＩＣ　＆　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ　ＬＥＴＴＥＲＳ ＶＯＬ．１５, 2005, Ｐ．２２７９-２２８３ *
JPN6013009134; ＡＣＴＡ　ＰＡＥＤＩＡＴＲ． ＶＯＬ．９０, 2001, Ｐ．１２５７-１２６１ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508744A (ja) * 2011-01-27 2014-04-10 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロピル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療
JP2016210808A (ja) * 2011-01-27 2016-12-15 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロピル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療
JP2018138606A (ja) * 2011-01-27 2018-09-06 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロピル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療
JP2016506380A (ja) * 2012-11-28 2016-03-03 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロリル−ｌ−グルタミン酸を使用する自閉症スペクトラム障害の処置
WO2021100614A1 (ja) * 2019-11-19 2021-05-27 国立大学法人京都大学 大豆ペプチド及び／又はコラーゲンペプチド含有神経心理学的機能改善剤

Also Published As

Publication number Publication date
CN101820896A (zh) 2010-09-01
EP2164509A1 (en) 2010-03-24
US7994127B2 (en) 2011-08-09
WO2008153929A1 (en) 2008-12-18
CA2689549A1 (en) 2008-12-18
BRPI0812768A2 (pt) 2014-12-02
AU2008262387A1 (en) 2008-12-18
US20120177630A1 (en) 2012-07-12
US20090099077A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
US7994127B2 (en) Treatment of rett syndrome
KR102436886B1 (ko) 신경퇴행성 장애
US20230381175A1 (en) Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders
RU2493868C2 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ
PT2275086E (pt) Formulação de volume reduzido de acetato de glatirâmero e métodos de administração
EA006860B1 (ru) Композиции и способы модулирования гемиканалов коннексина
US12421280B2 (en) Insulin like growth factor binding protein bioactive peptide fragments
BR112013014642A2 (pt) produto farmacêutico, kit, uso, produtos, métodos e usos inovadores
RU2491955C2 (ru) Активные растворимые изоформы нейрегулина, несущие посттрансляционные модификации
EP3448388B1 (en) Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases
US12582616B2 (en) Molecular targets for modulation of dissociative and associative states
RU2655811C2 (ru) Терапевтическое средство для бокового амиотрофического склероза
ES2617309T3 (es) Métodos y ensayos de tratamiento de sujetos con eliminación, mutación o expresión reducida de SHANK3
WO2025179292A1 (en) Compositions, systems, and methods for treating or reducing hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates
Zhang et al. Cholecystokinin B receptor agonists alleviates anterograde amnesia in CCK-deficient and aged Alzheimer's disease mice
US20190091284A1 (en) Amidated Dopamine Neuron Stimulating Peptides for CNS Dopaminergic Upregulation
JP2021522283A (ja) 分子ピンセットによるリポフスチンの凝集の阻害
US11931403B2 (en) Compositions, systems, and methods for treating or reducing hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates
US20180326014A1 (en) Pharmaceutical formulations for the treatment of diabetes
US20180117113A1 (en) Amidated Dopamine Neuron Stimulating Peptide Restoration of Mitochondrial Activity
JP2022104448A (ja) 認知症治療薬
TWI781073B (zh) 正丁烯基苯酞的醫藥用途
US20240398792A1 (en) Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease
Dhillon On the roles of hypothalamic tanycytes in energy homeostasis
WO2025179250A1 (en) Methods for the prophylaxis and treatment of autism related disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130806